Day One Biopharmaceuticals Insider Sold Shares Worth $320,226, According to a Recent SEC Filing

Samuel C. Blackman, Head of R&D, on July 16, 2024, sold 20,000 shares in Day One Biopharmaceuticals (DAWN) for $320,226. Following the Form 4 filing with the SEC, Blackman Samuel C. has control over

MT NewswiresJul 17 16:57 ET

We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.

Simply Wall StJul 12 12:28 ET

Day One Biopharm Price Target Maintained With a $40.00/Share by Piper Sandler

Day One Biopharm Price Target Maintained With a $40.00/Share by Piper Sandler

Dow JonesJul 8 09:19 ET

Piper Sandler Keeps Their Buy Rating on Day One Biopharmaceuticals (DAWN)

TipRanksJul 8 06:47 ET

Insider Selling: Director Saira Ramasastry Sells Shares of Day One Biopharmaceuticals Inc (DAWN)

Yahoo FinanceJun 22 04:11 ET

Day One Biopharmaceuticals(DAWN.US) Director Sells US$131.88K in Common Stock

$Day One Biopharmaceuticals(DAWN.US)$ Director Ramasastry Saira sold 10,000 shares of common stock on Jun 21, 2024 at an average price of $13.1877 for a total value of $131.88K.Source: Announcement Wh

Moomoo NewsJun 21 19:59 ET